Details of the Drug Combination

General Information of Drug Combination (ID: DC3LHZK)

Drug Combination Name
Fedratinib Ivosidenib
Indication
Disease Entry Status REF
IDH Mutation Phase 1 [1]
Component Drugs Fedratinib   DM4ZBK6 Ivosidenib   DM8S6T7
Small molecular drug N.A.
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Fedratinib
Disease Entry ICD 11 Status REF
Myelofibrosis 2A20.2 Approved [2]
Polycythemia vera 2A20.4 Approved [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Investigative [4]
Fedratinib Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Janus kinase 2 (JAK-2) TTRMX3V JAK2_HUMAN Inhibitor [2]
HUMAN janus kinase 2 (JAK-2) TT0F5HE JAK2_HUMAN Inhibitor [4]
------------------------------------------------------------------------------------
Fedratinib Interacts with 4 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Suppressor of cytokine signaling 3 (SOCS3) OTY183WJ SOCS3_HUMAN Decreases Expression [9]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Decreases Expression [8]
G1/S-specific cyclin-D1 (CCND1) OT8HPTKJ CCND1_HUMAN Decreases Expression [8]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Increases Expression [8]
------------------------------------------------------------------------------------
Indication(s) of Ivosidenib
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Approved [5]
Cholangiocarcinoma 2C12.10 Phase 3 [6]
Haematological malignancy 2B33.Y Phase 1 [7]
Ivosidenib Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Oxalosuccinate decarboxylase (IDH1) TTV2A1R IDHC_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------
Ivosidenib Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [10]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04955938) A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
3 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 212327
4 TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib. J Microbiol Immunol Infect. 2020 Mar 11. pii: S1684-1182(20)30065-7.
5 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
6 ClinicalTrials.gov (NCT02989857) Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) (ClarIDHy). U.S. National Institutes of Health.
7 ClinicalTrials.gov (NCT02073994) Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation. U.S. National Institutes of Health.
8 Differences in gene expression and alterations in cell cycle of acute myeloid leukemia cell lines after treatment with JAK inhibitors. Eur J Pharmacol. 2015 Oct 15;765:188-97. doi: 10.1016/j.ejphar.2015.08.037. Epub 2015 Aug 20.
9 The antimicrobial drug pyrimethamine inhibits STAT3 transcriptional activity by targeting the enzyme dihydrofolate reductase. J Biol Chem. 2022 Feb;298(2):101531. doi: 10.1016/j.jbc.2021.101531. Epub 2021 Dec 23.
10 DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB14568)